Cefaclor

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Cefaclor
   1. Pharmacist Assessment Report
   2. Cefaclor: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Cefaclor: Known uses and market status in Australia

Summary

The TxGNN model has no candidate indication with a score of 0.99 or higher for Cefaclor, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They are relations recorded in the knowledge graph, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	10
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
common cold
pharyngitis
pneumonia
respiratory tract infectious disease
staphylococcal infection
staphylococcus aureus infection
streptococcal infection
streptococcal pneumonia
tonsillitis
urinary tract infection

Australia Market Information

Licence	Product	Dosage form	Status
1169M	Ceclor CD	Tablet (sustained release) 375 mg (as mo	Valid

Safety Considerations

• Contraindications (from knowledge graph, not label text): Clostridium difficile colitis; perinatal necrotizing enterocolitis.
• Drug Interactions: 69 interactions were identified. Moderate-level interactions include balsalazide, picosulfuric acid, magnesium hydroxide and aluminium hydroxide. Other listed interactions (severity unknown) include calcitriol, pantoprazole, mesalazine, doxycycline, morphine, metformin, omeprazole, lansoprazole, cimetidine and several corticosteroids.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---